BioMaxima SA
WSE:BMX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| PL |
B
|
BioMaxima SA
WSE:BMX
|
51.8m PLN |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
63.4B USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.6T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
32.9B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
110.1B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.6B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
5B GBP |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6.5B USD |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
41.1B CNY |
Loading...
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
893.1B JPY |
Loading...
|
|
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5B USD |
Loading...
|
Market Distribution
| Min | -535 500% |
| 30th Percentile | 18.1% |
| Median | 30.2% |
| 70th Percentile | 55.9% |
| Max | 807.1% |
Other Profitability Ratios
BioMaxima SA
Glance View
Biomaxima SA operates in the field of biotechnology and laboratory diagnostics. The company is headquartered in Lublin, Woj. Lubelskie. The company went IPO on 2010-06-08. The company manufactures and distributes reagents and equipment for the laboratory diagnosis. The company produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The firm supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for BioMaxima SA is 48.7%, which is above its 3-year median of 46.8%.
Over the last 3 years, BioMaxima SA’s Gross Margin has increased from 40.2% to 48.7%. During this period, it reached a low of 39.6% on Dec 31, 2022 and a high of 49% on Jun 30, 2025.
